Publications – Associate Professor Sunil Badve

2019

Yeung WG, Toussaint ND, Badve SV. Dual Inhibition of Gastrointestinal Phosphate Absorption: More Questions Than Answers. J Am Soc Nephrol. 2019;30(6): 909-910.

Viecelli AK, Polkinghorne KR, Pascoe EM, et al. Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS One. 2019;14(3): e0213274.

Lioufas N, Toussaint ND, Pedagogos E, et al. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study. BMJ Open. 2019;9(2): e024382.

Li J, Badve SV, Zhou Z, et al. The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. The Lancet Rheumatology. 2019;1(4): e220-e228.

Ha JT, Neuen BL, Cheng LP, et al. Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med. 2019;171(3): 181-189.

Ha JT, Badve SV, Jun M. Recent evidence for direct oral anticoagulants in chronic kidney disease. Current opinion in nephrology and hypertension. 2019;28(3): 251-261.

Boudville N, Ullah S, Clayton P, et al. Differences in peritoneal dialysis technique survival between patients treated with peritoneal dialysis systems from different companies. Nephrol Dial Transplant. 2019;34(6): 1035-1044

2018

Boudville N, Ullah S, Clayton P, Sud K, Borlace M, Badve SV, Chakera A, Johnson DW. Differences in peritoneal dialysis technique survival between patients treated with peritoneal dialysis systems from different companies. Nephrol Dial Transplant. 2018 Dec 14. doi: 10.1093/ndt/gfy340. [Epub ahead of printing).

Htay H, Johnson DW, Wiggins KJ, Badve SV, Craig JC, Strippoli GF, Cho Y. Biocompatible dialysis fluids for peritoneal dialysis. Perit Dial Int. 2018. Jul-Aug;38(4):257-265. doi: 10.3747/pdi.2017.00199. Epub 2018 Feb 7

Htay H, Cho Y, Pascoe EM, Darssan D, Nadeau-Fredette AC, Hawley C, Clayton PA, Borlace M,Badve SV, Sud K, Boudville N, McDonald SP, Johnson DW. Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry. Am J Kidney Dis. 2018 Aug; 72(2):188-197. doi: 10.1053/j.ajkd.2017.10.019. Epub 2017 Dec 23.

Htay H, Cho Y, Pascoe EM, Badve SV, et al. Outcomes of Acinetobacter Peritonitis in Peritoneal Dialysis Patients: A Multicentre Registry Analysis. Perit Dial Int 2018;38:257-265.

Jegatheesan D, Johnson DW, Cho Y, Badve SV, et al. The Relationship between Body Mass Index and Organism-Specific Peritonitis. Perit Dial Int. 2018;38:206-214.

Lo C, Toyama T, Wang Y, Badve SV, et al. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev 2018;9CD011798.

See EJ, Johnson DW, Hawley CM, Pascoe EM, Badve SV, Boudville N, Clayton PA, Sud K, Polkinghorne KR, Borlace M and Cho Y. Risk Predictors and Causes of Technique Failure Within the First Year of Peritoneal Dialysis: An Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Study. Am J Kidney Dis, 2018-08-01, Volume 72, Issue 2, Pages 188-197

Tiku A, Badve SV, Johnson DW. Urate-Lowering Therapy for Preventing Kidney Disease Progression: Are We There Yet? Am J Kidney Dis. 2018 Dec;72(6):776-778. doi: 10.1053/j.ajkd.2018.07.022.

Wong ATY, Mannix C, Grantham JJ, Allman-Farinelli M, Badve SV, Boudville N, Byth K, Chan J, Coulshed S, Edwards ME, Erickson BJ, Fernando M, Foster S, Haloob I, Harris DCH, Hawley CM, Hill J, Howard K, Howell M, Jiang SH, Johnson DW, Kline TL, Kumar K, Lee VW, Lonergan M, Mai J, McCloud P, Peduto A, Rangan A, Roger SD, Sud K, Torres V, Vliayuri E, Rangan GK. Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open. 2018 Jan 21;8(1):e018794. doi: 10.1136/bmjopen-2017-018794. Erratum in: BMJ Open. 2018 Aug 5;8(8):e018794corr1.

2017

Committee HTW, Zhang L, Badve SV et al. Representativeness of Honeypot Trial Participants to Australasian PD Patients. Perit Dial Int 2017;37:516-522.

Chan S, Cho Y, Koh YH, Badve SV et al. Association of Socio-Economic Position with Technique Failure and Mortality in Australian Non-Indigenous Peritoneal Dialysis Patients. Perit Dial Int 2017;37:397-406.

Htay H, Cho Y, Pascoe EM, Badve SV et al. Outcomes of Corynebacterium Peritonitis: A Multicenter Registry Analysis. Perit Dial Int 2017;37:619- 626.

Htay H, Cho Y, Pascoe EM, Badve SV et al. Multicenter Registry Analysis of Center Characteristics Associated with Technique Failure in Patients on Incident Peritoneal Dialysis. Clin J Am Soc Nephrol 2017;12:1090-1099.

Irish AB, Viecelli AK, Hawley CM, Badve SV et al. Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis: A Randomized Clinical Trial. JAMA Intern Med 2017;177:184-193.

Lim WH, Badve SV, Wong G. Long-term allograft and patient outcomes of kidney transplant recipients with and without incident cancer – a population cohort study. Oncotarget 2017; 8:77771-77782.

Lo C, Jun M, Badve SV et al. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. Cochrane Database Syst Rev 2017;2:CD009966.

Roberts MA, Darssan D, Badve SV et al. Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial. Kidney Blood Press Res 2017;42:1033-1044.

See EJ, Johnson DW, Hawley CM, Badve SV et al. Early Peritonitis and Its Outcome in Incident Peritoneal Dialysis Patients. Perit Dial Int 2017.

Wong ATY, Mannix C, Grantham JJ, Badve SV et al. Randomised controlled trial to determine efficacy and safety of water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open 2017;7:e018794.

2016

Badve SV, Palmer SC, Hawley CM, Pascoe EM, Strippoli GF, Johnson DW. Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials. Nephrol Dial Transplant. 2016 Sep;31(9):1425-36.

Badve SV, Palmer SC, Strippoli GF, Roberts MA, Teixeira-Pinto A, Boudville N, Cass A, Hawley CM, Hiremath SS, Pascoe EM, Perkovic V, Whalley GA, Craig JC, Johnson DW. The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2016 Oct;68(4):554-63.

Badve SV, Pascoe EM, Burke M, Clayton PA, Campbell SB, Hawley CM, Lim WH,McDonald SP, Wong G, Johnson DW. Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1845-1855.

Gummer J, Trengove R, Pascoe EM, Badve SV, Cass A, Clarke P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW, Olynyk JK, Ferrari P; HERO Study Collaborative Group. Association between Serum Hepcidin-25 and Primary Resistance to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: A Secondary Analysis of the HERO Trial. Nephrology (Carlton). 2016 May 12. doi: 10.1111/nep.12815.

Lan PG, Clayton PA, Johnson DW, McDonald SP, Borlace M, Badve SV, Sud K,Boudville N. Duration of Hemodialysis Following Peritoneal Dialysis Cessation in Australia and New Zealand: Proposal for a Standardized Definition of Technique Failure. Perit Dial Int. 2016 11-12;36(6):623-630.

Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GF. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. 2016 Jul 19;316(3):313-24.

Nadeau-Fredette AC, Johnson DW, Hawley CM, Pascoe EM, Cho Y, Clayton PA,

Borlace M, Badve SV, Sud K, Boudville N, McDonald SP. Center-Specific Factors

Associated with Peritonitis Risk-A Multi-Center Registry Analysis. Perit Dial Int. 2016 9-10;36(5):509-18.

Roberts MA, Pilmore HL, Ierino FL, Badve SV, Cass A, Garg AX, Isbel NM, Krum H, Pascoe EM, Perkovic V, Scaria A, Tonkin AM, Vergara LA, Hawley CM; BLOCADE Study Collaborative Group.. The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. Am J Kidney Dis. 2016 Jun;67(6):902-11.

Sukkar L, Hong D, Wong MG, Badve SV, Rogers K, Perkovic V, Walsh M, Yu X, Hillis GS, Gallagher M, Jardine M. Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: systematic review and meta-analysis. BMJ. 2016 Nov 7;355:i5599. doi: 10.1136/bmj.i5599.

Viecelli AK, Pascoe EM, Polkinghorne KR, Hawley CM, Paul-Brent PA, Badve SV,Cass A, Johnson DW, Kerr PG, Mori TA, Scaria A, Hooi LS, Ong LM, Irish AB; FAVOURED study team. Updates on Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology (Carlton). 2016 Mar;21 (3): 217-28.

Young V, Balaam S, Orazio L, Bates A, Badve SV, Johnson DW, Campbell KL. Appetite predicts intake and nurtitional status in patients receiving peritoneal dialysis.   J Ren Care. 2016 Jun;42(2):123-31.

Zhang L, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, de Zoysa J, Isbel NM,Liu X, McTaggart S, Morrish AT, Playford G, Scaria A, Snelling P, Vergara LA,Hawley CM, Johnson DW. Representativeness of Honeypot Trial Participants to Australasian PD Patients. Perit Dial Int. 2016 Dec 1. pii: pdi.2016.00065. doi:10.3747/pdi.2016.00065.

Zhang L, Lee G, Liu X, Pascoe EM, Badve SV, Boudville NC, Clayton PA,  Hawley CM, Kanellis J, McDonald SP, Peh CA, Polkinghorne KR, Johnson DW. Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. Kidney Int. 2016 Jun;89(6):1337-45.

Zhang L, Liu X, Pascoe EM, Badve SV, Boudville NC, Clayton PA, De Zoysa J, Hawley CM, Kanellis J, McDonald SP, Peh CA, Polkinghorne KR, Johnson DW. Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study. Nephrology (Carlton). 2016 May;21(5):387-96.

2015

Badve SV, Zhang L, Coombes JS et al. Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Can J Kidney Health Dis 2015;2:33.

Badve SV, Palmer SC, Johnson DW, Strippoli GF. A nephrology guide to reading and using systematic reviews of randomized trials. Nephrol Dial Transplant 2015;30:878-84.

Badve SV, Palmer SC, Hawley CM, Pascoe EM, Strippoli GF, Johnson DW. Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials. Nephrol Dial Transplant 2015:doi:10.1093/ndt/gfv269.

Mallett A, Tang W, Hart G, Badve SV, et al. End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy – Outcomes in 66 Consecutive ANZDATA Registry Cases. Am J Nephrol 2015;42:177-84.

Nadeau-Fredette AC, Badve SV, Johnson DW. Daily home hemodialysis: balancing cardiovascular benefits with infectious harms. Am J Kidney Dis 2015;65:6-8.

Roberts MA, Pilmore HL, Ierino FL, Badve SV et al. The beta-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. Am J Kidney Dis 2015. doi: 10.1053/j.ajkd.2015.10.029

Roberts MA, Pilmore HL, Ierino FL, Badve SV. et al. The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study. Nephrology (Carlton) 2015;20:140-7.

Viecelli AK, Pascoe E, Polkinghorne KR, Badve SV et al. The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrol 2015;16:89.

Zhang L, Coombes J, Pascoe EM, Badve SV et al. The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox Rep 2015. doi:1179/1351000215Y.0000000022

Zhang L, Liu X, Pascoe EM, Badve SV. et al. Long term outcomes of end stage kidney disease for patients with IgA nephropathy: A multi-center registry study. Nephrology (Carlton) 2015. doi: 10.1111/nep.12629

Zhang L, Badve SV, Pascoe EM et al. The Effect of Exit-Site Antibacterial Honey Versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the Honeypot Trial. Perit Dial Int 2015;35:712-21.